<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4824">
  <stage>Registered</stage>
  <submitdate>6/01/2014</submitdate>
  <approvaldate>6/01/2014</approvaldate>
  <nctid>NCT02030418</nctid>
  <trial_identification>
    <studytitle>The LEADLESS Pacemaker IDE Study (Leadless II)</studytitle>
    <scientifictitle>Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DC-02374</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bradycardia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Leadless Pacemaker

Experimental: Leadless Pacemaker - VVIR pacing


Treatment: devices: Leadless Pacemaker
Patients will undergo an attempted leadless pacemaker implant

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Complication-Free Rate</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pacing thresholds and R-wave amplitudes within the therapeutic range</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>appropriate and proportional rate response during graded exercise testing</outcome>
      <timepoint>3-6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject must have one of the clinical indications before device implant in adherence
             with Medicare, ACC/AHA/HRS/ESC single chamber pacing guidelines including:

               -  Chronic and/or permanent atrial fibrillation with 2 or 3° AV or bifascicular
                  bundle branch block (BBB block), including slow ventricular rates (with or
                  without medication) associated with atrial fibrillation; or

               -  Normal sinus rhythm with 2 or 3° AV or BBB block and a low level of physical
                  activity or short expected lifespan (but at least one year); or

               -  Sinus bradycardia with infrequent pauses or unexplained syncope with EP findings;
                  and

          2. Subject =18 years of age; and

          3. Subject has life expectancy of at least one year; and

          4. Subject is not enrolled in another clinical investigation; and

          5. Subject is willing to comply with clinical investigation procedures and agrees to
             return for all required follow-up visits, tests, and exams; and

          6. Subject has been informed of the nature of the study, agrees to its provisions and has
             provided written informed consent, approved by the IRB; and

          7. Subject is not pregnant and does not plan to get pregnant during the course of the
             study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject has pacemaker syndrome, has retrograde VA conduction or suffers a drop in
             arterial blood pressure with the onset of ventricular pacing; or

          2. Subject is allergic or hypersensitive to &lt;1 mg of dexamethasone sodium phosphate; or

          3. Subject has a mechanical tricuspid valve prosthesis; or

          4. Subject has a pre-existing endocardial pacing or defibrillation leads; or

          5. Subject has current implantation of either conventional or subcutaneous implantable
             cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT); or

          6. Subject has an implanted vena cava filter; or

          7. Subject has evidence of thrombosis in one of the veins used for access during the
             procedure; or

          8. Subject has an implanted leadless cardiac pacemaker; or

          9. Subject had recent cardiovascular or peripheral vascular surgery within 30 days of
             enrollment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1567</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA</recruitmentstate>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode> - Chermside</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective, non-randomized, single-arm, international multicenter, clinical safety and
      effectiveness of a leadless pacemaker system in patients who are indicated for a VVIR
      pacemaker.

      Following completion of enrollments in the IDE, patients will continue to be enrolled in the
      continued access phase of the study under the same protocol.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02030418</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vivik Reddy, MD</name>
      <address>Mount Sinai Hospital, New York</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>